Company Filing History:
Years Active: 2008
Title: Innovator Spotlight: Elizabeth L. Thomson
Introduction: Elizabeth L. Thomson, a distinguished inventor based in Miami, FL, has made significant contributions to the field of immunology with her innovative research and patent. With one patent to her name, she has positioned herself as a driving force in developing therapeutic applications for cancer treatment, particularly targeting the p53 protein.
Latest Patents: Elizabeth holds a notable patent for "P53 binding T cell receptor molecules." This invention highlights the design of T-cell receptor (TCR) molecules, consisting of both Vα and Vβ chains that effectively bind to peptides sourced from the p53 protein, specifically the human variant. The TCR molecules are versatile, including heterodimeric and single-chain forms that target a sequence spanning amino acid positions 264-272 of the p53 protein presented in conjunction with the HLA-A2.1 molecule. Moreover, the patent outlines the methods for creating and utilizing these TCR molecules, emphasizing their potential for therapeutic applications and diagnostic uses in identifying cells that express the p53 protein.
Career Highlights: Elizabeth L. Thomson is currently affiliated with Altor Bioscience Corporation, where she continues to advance her research in T-cell therapies. Her work aims to address critical challenges within the realm of cancer immunotherapy, underlining her pivotal role in scientific innovation. The practical implications of her patent extend beyond basic research, demonstrating her commitment to translating scientific discoveries into real-world treatments.
Collaborations: In her career, Elizabeth has collaborated with esteemed colleagues such as Linda A. Sherman and Kimberlyn F. Card. These partnerships reflect a synergy of expertise, contributing to the development of groundbreaking therapeutic strategies in the biomedical sector.
Conclusion: Elizabeth L. Thomson's ingenuity and dedication have paved the way for advancements in cancer treatment through her innovative work on T-cell receptor molecules. With her patent and collaborations, she stands at the forefront of research that promises to enhance therapeutic approaches and improve patient outcomes in oncology. As she continues her work at Altor Bioscience Corporation, her contributions will likely foster new hope in the fight against cancer.